HIV testing and antiretroviral treatment strategies for prevention of HIV infection: Impact on antiretroviral drug resistance

Journal of Internal Medicine

Volumn 270, Issue 6, 2011, Pages 532-549

  Nichols, B E ^a   Boucher, C A B ^a   van de Vijver, D A M C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiretroviral drugs; Drug resistance; Human immunodeficiency virus; Prevention; Test and treat

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

BEHAVIOR CHANGE; CD4 LYMPHOCYTE COUNT; CIRCUMCISION; CLINICAL PRACTICE; CONFERENCE PAPER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MASS SCREENING; TIME FACTORS; VIRAL LOAD;

EID: 81855218587     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02456.x     Document Type: Conference Paper

References (145)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: UNAIDS, 2010.
2. UNAIDS. Key Facts by Region - 2008 Report on the Global AIDS Epidemic. Geneva: UNAIDS. 2008; 1-3.
3. Montaner JS, Hogg R, Wood E et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368: 531-6.
4. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20: 1447-50.
5. Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-9.
6. Donnell D, Baeten JM, Kiarie J et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-8.
7. Bunnell R, Ekwaru JP, Solberg P et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20: 85-92.
8. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23: 1397-404.
9. Reynolds SJ, Makumbi F, Nakigozi G et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25: 473-7.
10. Del Romero J, Castilla J, Hernando V, Rodriguez C, Garcia S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 2010; 340: c2205.
11. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
12. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
13. Cohen MS, Mastro TD, Cates Jr W. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1077; author reply 80-1.
14. Jurgens R, Cohen J, Tarantola D, Heywood M, Carr R. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1079; author reply 80-1.
15. Jaffe H, Smith A, Hope T. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1080; author reply -1.
16. Epstein H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1078-9; author reply 80-1.
17. Hsieh YH, de Arazoza H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1079-80; author reply 80-1.
18. Wilson DP. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1077-8; author reply 80-1.
19. Ruark A, Shelton JD, Halperin DT, Wawer MJ, Gray RH. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373: 1078; author reply 80-1.
20. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet 2010; 376: 953-4.
21. Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
22. van deVijver DAMC, Wensing AMJ, Boucher CAB et al. The epidemiology of transmission of drug resistant HIV-1. HIV Sequence Compendium 2006/2007. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR 07-4826. 2007; 17-36.
23. Chan PA, Kantor R. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Therapy 2009; 3: 447-65.
24. Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
25. Schuurman R, Nijhuis M, van Leeuwen R et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171: 1411-9.
26. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287: 650-4.
27. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2: 487-93.
28. Lima VD, Johnston K, Hogg RS et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198: 59-67.
29. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24: 729-35.
30. Walensky RP, Paltiel AD, Losina E et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51: 392-400.
31. Bendavid E, Brandeau ML, Wood R, Owens DK. Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med 2010; 170: 1347-54.
32. Phillips A. Will the drugs still work? Transmission of resistant HIV. Nat Med 2001; 7: 993-4.
33. Sloot PMA, Ivanov SV, Boukhanosky AV, van de vijver DAMC, Boucher CAB. Stochastic simulation of HIV population dynamics through complex network modeling. Int J Computer Math 2008; 85: 1175-87.
34. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224-36.
35. Cremin I, Nyamukapa C, Sherr L et al. Patterns of self-reported behaviour change associated with receiving voluntary counselling and testing in a longitudinal study from Manicaland, Zimbabwe. AIDS Behav 2010; 14: 708-15.
36. Palella Jr FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
37. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198: 687-93.
38. Gill VS, Lima VD, Zhang W et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50: 98-105.
39. Montaner JS, Lima VD, Barrios R et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376: 532-9.
40. Das MC P, Santos G-M, Scheer S, McFarland W, Vittinghoff E, Colfax G Success of test and treat in San Francisco? reduced time to virological suppression, decreased community viral load, and fewer new HIV infections, 2004 to 2009. Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. 2011.
41. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146: 591-601.
42. Alsop Z. Kenya's HIV-testing drive runs into difficulties. Lancet 2010; 375: 1242.
43. Charlebois ED, Havlir DV. 'A bird in the hand...': a commentary on the test and treat approach for HIV. Arch Intern Med 2010; 170: 1354-6.
44. Pilcher CD, Joaki G, Hoffman IF et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21: 1723-30.
45. Pilcher CD, Christopoulos KA, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. J Infect Dis 2010; 201(Suppl 1): S7-15.
46. Potts M, Halperin DT, Kirby D et al. Public health. Reassessing HIV prevention. Science 2008; 320: 749-50.
47. Wawer MJ, Makumbi F, Kigozi G et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374: 229-37.
48. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643-56.
49. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-66.
50. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (Online) 2009; 1: 37.
51. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000; 355: 1981-7.
52. Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346: 530-6.
53. Green EC, Halperin DT, Nantulya V, Hogle JA. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav 2006; 10: 335-46. discussion 47-50.
54. Stoneburner RL, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. Science 2004; 304: 714-8.
55. Shelton JD, Halperin DT, Nantulya V, Potts M, Gayle HD, Holmes KK. Partner reduction is crucial for balanced 'ABC' approach to HIV prevention. BMJ 2004; 328: 891-3.
56. Albert LM, Akol A, L'Engle K et al. Acceptability of male circumcision for prevention of HIV infection among men and women in Uganda. AIDS Care 2011; iFirst: 1-8.
57. Scott BE, Weiss HA, Viljoen JI. The acceptability of male circumcision as an HIV intervention among a rural Zulu population, Kwazulu-Natal, South Africa. AIDS Care 2005; 17: 304-13.
58. Mavhu W, Buzdugan R, Langhaug LF et al. Prevalence and factors associated with knowledge of and willingness for male circumcision in rural Zimbabwe. Trop Med Int Health 2011; 16: 589-97.
59. Le Vu S, Le Strat Y, Barin F et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010; 10: 682-7.
60. Wand H, Yan P, Wilson D et al. Increasing HIV transmission through male homosexual and heterosexual contact in Australia: results from an extended back-projection approach. HIV Med 2010; 11: 395-403.
61. Wiysonge CS, Kongnyuy EJ, Shey M et al. Male circumcision for prevention of homosexual acquisition of HIV in men. Cochrane Database Syst Rev (Online) 2011:CD007496.
62. Wawer MJ, Sewankambo NK, Serwadda D et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353: 525-35.
63. White RG, Moodley P, McGrath N et al. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sex Transm Infect 2008; 84: 528-34.
64. Levy I, Mor Z, Anis E et al. Men who have sex with men, risk behavior, and HIV infection: integrative analysis of clinical, epidemiological, and laboratory databases. Clin Infect Dis 2011; 52: 1363-70.
65. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
66. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26.
67. Ray M, Logan R, Sterne JA et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (London, England) 2010; 24: 123-37.
68. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-63.
69. Collaboration TH-C. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154: 509-15.
70. Prosperi MC, Cozzi-Lepri A, Castagna A et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 1316-21.
71. Phillips A, Costagliola D, Sabin C, Sterne J. Early initiation of treatment for HIV infection. Lancet 2010; 375: 639.
72. Chic U. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010; 24: 723-7.
73. Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010; 50: 1512-20.
74. McNeil Jr DG. At front lines, AIDS war Is falling apart. New York Times, 10 May, 2010. (New York) Accessed on 1 March 2011 at.
75. WHO. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: World Health Organisation. 2009; 1-28. Accessed 1 March 2011 at.
76. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4: e298.
77. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: Rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2011; 56: e79-86.
78. Gupta RK, Hill A, Sawyer AW et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 409-17.
79. Hoffmann CJ, Charalambous S, Sim J et al. Viremia, resuppression, and time to resistance in Human Immunodeficiency Virus (HIV) subtype C DURING first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009; 49: 1928-35.
80. Ndembi N, Goodall RL, Dunn DT et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 2010; 201: 106-13.
81. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376: 49-62.
82. Boyd M, Emery S, Cooper DA. Antiretroviral roll-out: the problem of second-line therapy. Lancet 2009; 374: 185-6.
83. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24: 915-9.
84. Spread-programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-35.
85. Yerly S, Vora S, Rizzardi P et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-92.
86. Brenner BG, Roger M, Routy JP et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195: 951-9.
87. Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-66.
88. UK-CHIC. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 2010; 50: 1275-85.
89. Ferradini L, Jeannin A, Pinoges L et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367: 1335-42.
90. El-Khatib Z, Ekstrom AM, Ledwaba J et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010; 24: 1679-87.
91. Messou E, Chaix ML, Gabillard D et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1 infected adults on antiretroviral therapy in Cote d'Ivoire. J Acquir Immune Defic Syndr 2011; 57(Suppl 1): S34-9.
92. Maldonado F, Biot M, Roman F et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg 2009; 103: 607-12.
93. Bussmann H, Wester CW, Thomas A et al. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009; 51: 37-46.
94. Johannessen A, Naman E, Kivuyo SL et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9: 108.
95. Laurent C, Kouanfack C, Koulla-Shiro S et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364: 29-34.
96. Koyalta D, Charpentier C, Beassamda J et al. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis 2009; 49: 155-9.
97. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21: 2455-64.
98. van de Vijver DA, Wensing AM, Angarano G et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41: 352-60.
99. Kuritzkes DR. Preventing and managing resistance in the clinical setting. J Acquir Immune Defic Syndr 2003; 34(Suppl 2): S103-10.
100. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 2002-11.
101. Boucher CA, O'Sullivan E, Mulder JW et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105-10.
102. Bygrave H, Ford N, Cutsem G et al. Implementing a tenofovir-based first-line regimen in rural lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr 2011; 56: e75-8.
103. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV-1 drug resistance through 144weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009; 52: 209-21.
104. Wensing AMJ, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5: 140-55.
105. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59: 1047-56.
106. Hamers RL, Derdelinckx I, van Vugt M et al. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008; 13: 625-39.
107. Price MA, Wallis CL, Lakhi S et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011; 27: 5-12.
108. Hamers RL, Siwale M, Wallis CL et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010; 55: 95-101.
109. Bussmann H, de la Hoz Gomez F, Roels TH et al. Prevalence of transmitted HIV Drug Resistance (HIVDR) in Botswana: lessons learned from the HIVDR-threshold survey conducted among women presenting for routine antenatal care as part of the 2007 National Sentinel Survey. AIDS Res Hum Retroviruses 2011; 27: 365-72.
110. Mosha F, Urassa W, Aboud S et al. Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths Infected with diverse HIV Type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2010; 27: 377-82.
111. Tebit DM, Sangare L, Tiba F et al. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso. J Med Virol 2009; 81: 1691-701.
112. Bartolo I, Casanovas J, Bastos R et al. HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. J Acquir Immune Defic Syndr 2009; 51: 323-31.
113. Aghokeng AF, Vergne L, Mpoudi-Ngole E et al. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 2009; 14: 401-11.
114. Eshleman SH, Laeyendecker O, Parkin N et al. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009; 23: 845-52.
115. Ayouba A, Lien TT, Nouhin J et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses 2009; 25: 1193-6.
116. Wheeler WH, Ziebell RA, Zabina H et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24: 1203-12.
117. Stringer JS, McConnell MS, Kiarie J et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, Prospective Cohort Study. PLoS Med 2010; 7: e1000233.
118. Lockman S, Hughes MD, McIntyre J et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363: 1499-509.
119. Jackson JB, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-68.
120. Cotton MF, Rabie H, van Zyl GU. Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next? Clin Infect Dis 2010; 50: 909-11.
121. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
122. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331: 1368.
123. Frentz D, Boucher CA, Assel M et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS ONE 2010; 5: e11505.
124. van deVijver DA, Wensing AM, Asjo B et al. HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. Acta Dermatovenerol Alp Panonica Adriat 2010; 19: 3-9.
125. Costagliola D, Descamps D, Assoumou L et al. Prevalence of HIV-1 drug resistance in treated patients: a French Nationwide Study. J Acquir Immune Defic Syndr 2007; 46: 12-8.
126. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14: 23-8.
127. Turner D, Brenner B, Routy JP et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1627-31.
128. Weber J, Chakraborty B, Weberova J, Miller MD, Quinones-Mateu ME. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 2005; 43: 1395-400.
129. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.
130. Peeters M, Toure-Kane C, Nkengasong JN. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 2003; 17: 2547-60.
131. Metzner KJ, Bonhoeffer S, Fischer M et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188: 1433-43.
132. Metzner KJ, Giulieri SG, Knoepfel SA et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009; 48: 239-47.
133. Metzner KJ, Rauch P, von Wyl V et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201: 1063-71.
134. Metzner KJ, Rauch P, Walter H et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19: 1819-25.
135. Paredes R, Lalama CM, Ribaudo HJ et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201: 662-71.
136. Bezemer D, van Sighem A, Lukashov VV et al. Transmission networks of HIV-1 among men having sex with men in the Netherlands. AIDS 2010; 24: 271-82.
137. Brenner BG, Roger M, Moisi DD et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008; 22: 2509-15.
138. Nederlandse vereniging van Ab. Richtlijn Antiretrovirale Behandeling. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO, 2005.
139. Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, Mills EJ. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 770-7.
140. Moore ZS, McCoy S, Kuruc J, Hilton M, Leone P. Number of named partners and number of partners newly diagnosed with HIV infection identified by persons with acute versus established HIV infection. J Acquir Immune Defic Syndr 2009; 52: 509-13.
141. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
142. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-99.
143. van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis 2010; 23: 621-7.
144. Paltiel AD, Freedberg KA, Scott CA et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48: 806-15.
145. van de Vijver DA, Derdelinckx I, Boucher CA. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009; 199: 1310-7.